Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Agenus (NASDAQ: AGEN) announced its participation in the ASCO 2023 Annual Meeting from June 2-6 in Chicago, IL, where it will present clinical data from key trials. An oral presentation on June 5 will detail a Phase 2 trial of balstilimab and zalifrelimab combined with doxorubicin for advanced sarcomas. Additionally, a poster discussion on June 3 will cover the monotherapy results of AGEN2373, a CD137 agonist, in advanced solid tumors. Abstracts will be available on May 25. Balstilimab and zalifrelimab are designed to enhance immune response against cancer, while AGEN2373 targets T and NK cells with reduced liver toxicity risks.